Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Takeda
Roswell Park Cancer Institute
Gamida Cell ltd
University of Rochester
M.D. Anderson Cancer Center
Brown University
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
Novartis
M.D. Anderson Cancer Center
Thomas Jefferson University
Takeda
National Institutes of Health Clinical Center (CC)
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
PharmaEssentia Japan K.K.
Novartis
Novartis
Incyte Corporation
Celgene
Masonic Cancer Center, University of Minnesota
Stanford University
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
Masonic Cancer Center, University of Minnesota
American Regent, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Novartis
M.D. Anderson Cancer Center
Fujifilm Pharmaceuticals U.S.A., Inc.
Aprea Therapeutics
Fred Hutchinson Cancer Center
City of Hope Medical Center
Icahn School of Medicine at Mount Sinai
BerGenBio ASA
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University